LIXTE BIOTECHNOLOGY HOLDINGS
Lixte Biotechnology Holdings, Inc. is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
LIXTE BIOTECHNOLOGY HOLDINGS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
East Setauket, New York, United States
Country:
United States
Website Url:
http://www.lixte.com
Total Employee:
1+
Status:
Active
Contact:
(631) 830-7092
Email Addresses:
[email protected]
Total Funding:
10.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Apache
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.lixte.com Semrush global rank: 1.24 M Semrush visits lastest month: 24.48 K
- Host name: 74-208-236-39.elastic-ssl.ui-r.com
- IP address: 74.208.236.39
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lixte Biotechnology Holdings"
LIXTE: Advancing novel oncology treatments and cancer therapies
Sep 4, 2024 · Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A …See details»
LIXTE Biotechnology Holdings, Inc. (LIXT)
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and …See details»
Income Statement :: LIXTE Biotechnology Holdings, Inc. (LIXT)
Nov 12, 2024 · Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments …See details»
LIXTE Biotechnology Provides Update On Recent Activities and ...
PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical …See details»
TEAM: Collective expertise in pioneering effective …
Founded LIXTE in 2005 in the hopes of finding better treatments for cancer and served as CEO, CSO & Exec Chair. Our team brings decades of collective expertise in drug development, ensuring comprehensive knowledge and …See details»
Lixte Biotechnology Holdings, Inc. | LinkedIn
Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified...See details»
Lixte Biotechnology - Crunchbase Company Profile & Funding
Lixte Biotechnology is a clinical-stage public pharmaceutical company that focuses on discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling …See details»
LIXTE Biotechnology Holdings Names Distinguished Oncologist …
Jun 3, 2024 · LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing …See details»
Lixte Biotechnology Holdings, Inc. (LIXT) Company Profile
Nov 15, 2024 · LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and …See details»
Lixte Biotechnology - Funding, Financials, Valuation & Investors
Lixte Biotechnology is a clinical-stage pharmaceutical company that focuses on discovering drugs for effective cancer treatments.See details»
News & Events :: LIXTE Biotechnology Holdings, Inc.
Aug 26, 2024 · Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments using PP2A inhibition with LB-100.See details»
LIXTE Biotechnology Enters into Exclusive Immune Oncology …
Feb 26, 2024 · LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing …See details»
Lixte Biotechnology Holdings, Inc. (LIXT) - Yahoo Finance
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer …See details»
LIXT Stock Price Quote | Morningstar
Sep 6, 2024 · See the latest Lixte Biotechnology Holdings Inc stock price (LIXT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
LIXTE Biotechnology Announces Closing of $3.5 Million Registered …
Jul 20, 2023 · LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing …See details»
Lixte Biotechnology Holdings, Inc. (LIXT) - Stock Analysis
6 days ago · Get a real-time Lixte Biotechnology Holdings, Inc. (LIXT) stock price quote with breaking news, financials, statistics, charts and more.See details»
Lixte Biotechnology Holdings, Inc. (LIXT) Stock Price, News, Quote ...
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer …See details»
LIXTE Biotechnology Announces $5.8 Million Registered Direct …
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active …See details»
Lixte Biotechnology Holdings, Inc. (LIXT) Stock Price, Quote, News ...
A high-level overview of Lixte Biotechnology Holdings, Inc. (LIXT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.See details»
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Throughout this Annual Report on Form 10-K, the terms “we,” “us,” “our,” “our company,” “Lixte,” the “Company” and the “Registrant” refer to Lixte Biotechnology Holdings, Inc., a Delaware …See details»